Sign in Subscribe
Biotechnology

Nucleome Therapeutics to Lead Oxford's First Purpose-Built Commercial Science Scheme

Strategic Insights

— 1 min read

Nucleome Therapeutics, a leading biotechnology company spun out from Oxford University, will occupy a significant portion of the newly built Inventa building in Oxford's West End. This state-of-the-art complex is the first commercial science scheme delivered in the city's West End, strategically located within walking distance of Oxford train station. As part of this partnership, Nucleome will relocate from its existing headquarters at the Oxford Science Park, taking advantage of the improved facilities and central location.

Key Takeaways:

  • Nucleome Therapeutics, a biotechnology company spun out from Oxford University, will occupy almost a third of the 65,000-square-foot Inventa building in Oxford's West End.
  • Nucleome aims to address traditional drug discovery failure rates by derisking novel targets through proprietary genomics approaches, having completed an oversubscribed £37.5m Series A funding round in 2022.
  • The company will relocate from its existing headquarters at the Oxford Science Park to the Inventa building, which was developed in partnership with Mission Street, a specialist developer for the science and innovation sector, and BGO, a leading global real estate investment.
  • Nucleome's partnership with Inventa is a significant step towards the company's growth, with a need for larger office and lab space driven by the significant progress in identifying new drug candidates.
  • The West End has a long-term pipeline of over two million sq ft of commercial and academic buildings, with a goal to become a global top three innovation cluster by 2040.

Statistics:

  • Nucleome Therapeutics will occupy almost 20,000 square feet of the 65,000-square-foot Inventa building.
  • The company completed an oversubscribed £37.5m Series A funding round in 2022, backed by investors including Oxford Science Enterprises, M Ventures, Pfizer Ventures, British Patient Capital, and Johnson & Johnson Innovation.
  • The West End has a long-term pipeline of over two million sq ft of commercial and academic buildings.
  • Construction for the 183,000 sq ft, five-storey Fabrica building in the West End is due to commence in September.

Sources:

  • "Nucleome Therapeutics to lead Oxford's first purpose-built commercial science scheme" (Robert Folker)
  • Mission Street
  • BGO
  • Oxford Science Enterprises
  • M Ventures
  • Pfizer Ventures
  • British Patient Capital
  • Johnson & Johnson Innovation
  • Oxford University

Read more